Black Diamond Therapeutics shares are trading higher after the company announced initial dose escalation data demonstrated anti-tumor activity of BDTX-1535 in non-small cell lung cancer patients across multiple EGFR mutation families.
Portfolio Pulse from Benzinga Newsdesk
Black Diamond Therapeutics announced initial dose escalation data showing anti-tumor activity of BDTX-1535 in non-small cell lung cancer patients across multiple EGFR mutation families, leading to higher trading of its shares.
June 27, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Black Diamond Therapeutics shares are trading higher after positive initial data on BDTX-1535's anti-tumor activity in non-small cell lung cancer patients.
The positive initial data on BDTX-1535's anti-tumor activity in non-small cell lung cancer patients indicates potential success for the drug, which could lead to increased revenue and growth for Black Diamond Therapeutics. This news is likely to have a positive short-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100